| Name | Title | Contact Details |
|---|
Andrus nurtures hope in children by providing care that empowers them to succeed and by promoting innovation and standards of excellence in the care of children in our community and beyond. Andrus nurtures social and emotional well-being in children and their families by delivering a broad range of vital services and by providing research, training and innovative program models that promote standards of excellence for professional performance in and beyond our service community.
Health Castle is a Port Coquitlam, BC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Seabury is an active life care community in Bloomfield, CT that offers independent living, assisted living, memory support, skilled nursing, and outpatient rehabilitation services.
DCPCA is a nonprofit health reform organization founded in 1996 by health care professionals who were concerned that the shortage of primary health care in the District was contributing to increasingly poor health outcomes for DC's most vulnerable residents. With a budget of $140,000 in seed money from the federal government's Bureau of Primary Care, Sharon Baskerville became DCPCA's first executive director in 1998. As DCPCA established itself in the late 1990s, District voters elected a new mayor and six new members of the DC Council. The improved political environment made it possible for the District's budget to emerge from direct federal control. Under these new conditions, DCPCA emerged as a health reform leader and quickly became the local voice promoting progressive health care financing and public policy, galvanizing political support at the local and federal levels.
Telesta Therapeutics is a biopharmaceutical company focused on the development, manufacturing and commercialization of transformative human therapeutics. Our main focus is on novel medicines that address major unmet medical needs, particularly in oncology. Our anchor product, MCNA, has completed a Phase III pivotal study in patients with non-muscle invasive bladder cancer that have failed the first line therapy, bacillus Calmette-Guérin (BCG). Telesta submitted a Biologics Licensing Application (BLA) for MCNA with the U.S. FDA on June 29, 2015 and is seeking, upon marketing approval in the U.S., to make MCNA available for patients and their physicians. Our ultimate goal is to transform the treatment landscape and prolong and improve the lives of those affected by bladder cancer, one of the most common types of cancers today.